Preparation for International Cooperation on Cosmetics Regulations; Public Meeting, 14405 [2012-5744]
Download as PDF
<![CDATA[
Federal Register / Vol. 77, No. 47 / Friday, March 9, 2012 / Notices
docket number found in brackets in the
heading of this document. Received
comments may be seen in the Division
of Dockets Management between 9 a.m.
and 4 p.m., Monday through Friday.
III. Electronic Access
Persons with access to the Internet
may obtain the document at https://
www.fda.gov/AdvisoryCommittees/
default.htm.
Dated: February 28, 2012.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2012–5776 Filed 3–8–12; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2012–N–0001]
Preparation for International
Cooperation on Cosmetics
Regulations; Public Meeting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of meeting.
The Food and Drug
Administration (FDA) is announcing a
public meeting entitled ‘‘International
Cooperation on Cosmetics Regulations
(ICCR)–Preparation for ICCR–6 Meeting
in Rockville, Maryland’’ to provide
information and receive comments on
the International Cooperation on
Cosmetics Regulations (ICCR) as well as
the upcoming meetings in Rockville,
MD. The topics to be discussed are the
topics for discussion at the forthcoming
ICCR Steering Committee meeting. The
purpose of the meeting is to solicit
public input prior to the next steering
committee and expert working group
meetings in Rockville, MD on July10 to
13, 2012.
Date and Time: The meeting will be
held on May 15, 2012, from 2 to 4 p.m.
Location: The meeting will be held in
the Washington Theater Room at the
Hilton Washington DC/Rockville Hotel
& Executive Meeting Center, 1750
Rockville Pike, Rockville, MD 20852.
Contact Person: All participants must
register with Kimberly Franklin, Office
of the Commissioner, Food and Drug
Administration, 10903 New Hampshire
Ave., Silver Spring, MD 20993, by
email: Kimberly.Franklin@fda.hhs.gov
or FAX: 301–595–7937.
Registration and Requests for Oral
Presentations: Send registration
information (including: Name, title, firm
name, address, telephone, and fax
number), written material and requests
srobinson on DSK4SPTVN1PROD with NOTICES
SUMMARY:
VerDate Mar<15>2010
16:21 Mar 08, 2012
Jkt 226001
to make oral presentation, to the contact
person by May 9, 2012.
If you need special accommodations
due to a disability, please contact
Kimberly Franklin (see Contact Person)
at least 7 days in advance.
Interested persons may present data,
information, or views orally or in
writing, on issues pending at the public
meeting. Time allotted for oral
presentations may be limited to 10
minutes. Those desiring to make oral
presentations should notify the contact
person by May 9, 2012, and submit a
brief statement of the general nature of
the evidence or arguments they wish to
present, the names and addresses,
telephone number, FAX and email of
the proposed participants, and an
indication of the approximate time
requested to make their presentation.
Transcripts: Please be advised that as
soon as a transcript is available, it will
be accessible at https://
www.regulations.gov. It may be viewed
at the Division of Dockets Management
(HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD. A transcript will
also be available in either hardcopy or
on CD–ROM, after submission of a
Freedom of Information request. Written
requests are to be sent to Division of
Freedom of Information (ELEM–1029),
Food and Drug Administration, 12420
Parklawn Dr., Element Bldg. Rockville,
MD 20857.
SUPPLEMENTARY INFORMATION: The
purpose of the multilateral framework
on the ICCR is to pave the way for the
removal of regulatory obstacles to
international trade while maintaining
global consumer protection.
ICCR is a voluntary international
group of cosmetics regulatory
authorities from the: United States,
Japan, the European Union, and Canada.
These regulatory authority members
will enter into constructive dialogue
with their relevant cosmetics’ industry
trade associations. Currently, the ICCR
members are: Health Canada; the
European Directorate General for
Enterprise and Industry; the Ministry of
Health, Labor and Welfare of Japan; and
the U.S. Food and Drug Administration.
All decisions made by consensus will be
compatible with the laws, policies,
rules, regulations, and directives of the
respective administrations and
governments. Members will implement
and/or promote actions or documents
within their own jurisdictions and seek
convergence of regulatory policies and
practices. Successful implementation
will require input from stakeholders.
Interested persons may present data,
information, or views orally or in
PO 00000
Frm 00067
Fmt 4703
Sfmt 4703
14405
writing, on issues pending at the public
meeting. Time allotted for oral
presentations may be limited to 10
minutes. Those desiring to make oral
presentations should notify the contact
person by April 22, 2011, and submit a
brief statement of the general nature of
the evidence or arguments they wish to
present, the names and addresses,
telephone number, fax, and email of
proposed participants, and an
indication of the approximate time
requested to make their presentation.
The agenda for the public meeting
will be made available on the Internet
at https://www.fda.gov/Cosmetics/
InternationalActivities/
ConferencesMeetingsWorkshops/
InternationalCooperationon
CosmeticsRegulationsICCR/default.htm.
Dated: March 6, 2012.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2012–5744 Filed 3–8–12; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; Ancillary Studies
for ISC Consortium.
Date: March 29, 2012.
Time: 2 p.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892, (Telephone
Conference Call).
Contact Person: Maria E. Davila-Bloom,
Ph.D., Scientific Review Officer, Review
Branch, DEA, NIDDK, National Institutes of
Health, Room 758, 6707 Democracy
Boulevard, Bethesda, MD 20892–5452, (301)
E:\FR\FM\09MRN1.SGM
09MRN1
]]>Agencies
[Federal Register Volume 77, Number 47 (Friday, March 9, 2012)]
[Notices]
[Page 14405]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-5744]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2012-N-0001]
Preparation for International Cooperation on Cosmetics
Regulations; Public Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice of meeting.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing a public
meeting entitled ``International Cooperation on Cosmetics Regulations
(ICCR)-Preparation for ICCR-6 Meeting in Rockville, Maryland'' to
provide information and receive comments on the International
Cooperation on Cosmetics Regulations (ICCR) as well as the upcoming
meetings in Rockville, MD. The topics to be discussed are the topics
for discussion at the forthcoming ICCR Steering Committee meeting. The
purpose of the meeting is to solicit public input prior to the next
steering committee and expert working group meetings in Rockville, MD
on July10 to 13, 2012.
Date and Time: The meeting will be held on May 15, 2012, from 2 to
4 p.m.
Location: The meeting will be held in the Washington Theater Room
at the Hilton Washington DC/Rockville Hotel & Executive Meeting Center,
1750 Rockville Pike, Rockville, MD 20852.
Contact Person: All participants must register with Kimberly
Franklin, Office of the Commissioner, Food and Drug Administration,
10903 New Hampshire Ave., Silver Spring, MD 20993, by email:
Kimberly.Franklin@fda.hhs.gov or FAX: 301-595-7937.
Registration and Requests for Oral Presentations: Send registration
information (including: Name, title, firm name, address, telephone, and
fax number), written material and requests to make oral presentation,
to the contact person by May 9, 2012.
If you need special accommodations due to a disability, please
contact Kimberly Franklin (see Contact Person) at least 7 days in
advance.
Interested persons may present data, information, or views orally
or in writing, on issues pending at the public meeting. Time allotted
for oral presentations may be limited to 10 minutes. Those desiring to
make oral presentations should notify the contact person by May 9,
2012, and submit a brief statement of the general nature of the
evidence or arguments they wish to present, the names and addresses,
telephone number, FAX and email of the proposed participants, and an
indication of the approximate time requested to make their
presentation.
Transcripts: Please be advised that as soon as a transcript is
available, it will be accessible at https://www.regulations.gov. It may
be viewed at the Division of Dockets Management (HFA-305), Food and
Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD. A
transcript will also be available in either hardcopy or on CD-ROM,
after submission of a Freedom of Information request. Written requests
are to be sent to Division of Freedom of Information (ELEM-1029), Food
and Drug Administration, 12420 Parklawn Dr., Element Bldg. Rockville,
MD 20857.
SUPPLEMENTARY INFORMATION: The purpose of the multilateral framework on
the ICCR is to pave the way for the removal of regulatory obstacles to
international trade while maintaining global consumer protection.
ICCR is a voluntary international group of cosmetics regulatory
authorities from the: United States, Japan, the European Union, and
Canada. These regulatory authority members will enter into constructive
dialogue with their relevant cosmetics' industry trade associations.
Currently, the ICCR members are: Health Canada; the European
Directorate General for Enterprise and Industry; the Ministry of
Health, Labor and Welfare of Japan; and the U.S. Food and Drug
Administration. All decisions made by consensus will be compatible with
the laws, policies, rules, regulations, and directives of the
respective administrations and governments. Members will implement and/
or promote actions or documents within their own jurisdictions and seek
convergence of regulatory policies and practices. Successful
implementation will require input from stakeholders.
Interested persons may present data, information, or views orally
or in writing, on issues pending at the public meeting. Time allotted
for oral presentations may be limited to 10 minutes. Those desiring to
make oral presentations should notify the contact person by April 22,
2011, and submit a brief statement of the general nature of the
evidence or arguments they wish to present, the names and addresses,
telephone number, fax, and email of proposed participants, and an
indication of the approximate time requested to make their
presentation.
The agenda for the public meeting will be made available on the
Internet at https://www.fda.gov/Cosmetics/InternationalActivities/ConferencesMeetingsWorkshops/InternationalCooperationonCosmeticsRegulationsICCR/default.htm.
Dated: March 6, 2012.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2012-5744 Filed 3-8-12; 8:45 am]
BILLING CODE 4160-01-P
